43 studies found for:
Open Studies | "Hypereosinophilic Syndrome"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Unknown † |
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
|
||||
| 2 | Recruiting |
Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
|
||||
| 3 | Recruiting |
Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)
|
||||
| 4 | Recruiting |
Steroid Treatment for Hypereosinophilic Syndrome
|
||||
| 5 | Recruiting |
Identification of New Markers in the Hypereosinophilic Syndrome
|
||||
| 6 | Recruiting |
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
|
||||
| 7 | Recruiting |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer
|
||||
| 8 | Recruiting |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
|
||||
| 9 | Recruiting |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
||||
| 10 | Recruiting |
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
|
||||
| 11 | Recruiting |
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
|
||||
| 12 | Recruiting |
Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant
|
||||
| 13 | Recruiting |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
||||
| 14 | Recruiting |
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
||||
| 15 | Recruiting |
Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
|
||||
| 16 | Not yet recruiting |
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
||||
| 17 | Recruiting |
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
||||
| 18 | Recruiting |
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
|
||||
| 19 | Unknown † |
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy
|
||||
| 20 | Recruiting |
Registry of Older Patients With Cancer
|
† Indicates status has not been verified in more than two years
